BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33835965)

  • 1. Prognostic Impact of Tumor Size on Pancreatic Neuroendocrine Tumor Recurrence May Have Racial Variance.
    Zheng-Pywell R; Fang A; AlKashash A; Awad S; Reddy S; Vickers S; Heslin M; Dudeja V; Chen H; Rose JB
    Pancreas; 2021 Mar; 50(3):347-352. PubMed ID: 33835965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study.
    Zhou H; Zhang Y; Wei X; Yang K; Tan W; Qiu Z; Li S; Chen Q; Song Y; Gao S
    Cancer Med; 2017 Nov; 6(11):2745-2756. PubMed ID: 28980417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Prognostic Factors of Early-Onset Pancreatic Neuroendocrine Tumors.
    Shi M; Zhou B
    Cancer Control; 2021; 28():1073274820986827. PubMed ID: 33491476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?
    DePalo DK; Lee RM; Lopez-Aguiar AG; Gamboa AC; Rocha F; Poultsides G; Dillhoff M; Fields RC; Idrees K; Nathan H; Abbott D; Maithel SK; Russell MC;
    J Surg Oncol; 2019 Nov; 120(6):919-925. PubMed ID: 31385621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features and prognosis factors for survival in elderly patients with pancreatic neuroendocrine tumor: A STROBE-compliant article.
    Li G; Tian ML; Bing YT; Tao LY; Wang HY; Jiang B; Yuan CH; Xiu DR
    Medicine (Baltimore); 2019 Mar; 98(11):e14576. PubMed ID: 30882623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
    Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
    Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
    Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
    JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors.
    Zaidi MY; Lopez-Aguiar AG; Dillhoff M; Beal E; Poultsides G; Makris E; Rocha F; Crown A; Idrees K; Marincola Smith P; Nathan H; Beems M; Abbott D; Barrett JR; Fields RC; Davidson J; Cardona K; Maithel SK
    JAMA Surg; 2019 Feb; 154(2):134-140. PubMed ID: 30383112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Validity of the American Joint Committee on Cancer Eighth Edition TNM Staging System for Surgically Treated and Well-Differentiated Pancreatic Neuroendocrine Tumors: A Comprehensive Analysis of 254 Consecutive Patients From a Large Chinese Institution.
    Yang M; Zhang Y; Zeng L; Ke NW; Tan CL; Tian BL; Xiang B; Liu XB
    Pancreas; 2019; 48(5):613-621. PubMed ID: 31091206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
    Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
    JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. It's more than just cancer biology: Health disparities in patients with pancreatic neuroendocrine tumors.
    Underwood PW; Riner AN; Neal D; Cameron ME; Yakovenko A; Reddy S; Rose JB; Hughes SJ; Trevino JG
    J Surg Oncol; 2021 Dec; 124(8):1390-1401. PubMed ID: 34499741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
    Kuo EJ; Salem RR
    Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors.
    Yang B; Chen HY; Zhang XY; Pan Y; Lu YF; Yu RS
    Eur J Radiol; 2020 Mar; 124():108847. PubMed ID: 31991300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases.
    Dong DH; Zhang XF; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM;
    J Surg Oncol; 2019 Dec; 120(7):1071-1079. PubMed ID: 31571225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy.
    Dong DH; Zhang XF; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Spolverato G; Maithel SK; Pawlik TM
    J Surg Oncol; 2020 Sep; 122(3):442-449. PubMed ID: 32470159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).
    Hashim YM; Trinkaus KM; Linehan DC; Strasberg SS; Fields RC; Cao D; Hawkins WG
    Ann Surg; 2014 Feb; 259(2):197-203. PubMed ID: 24253141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
    Bilimoria KY; Bentrem DJ; Merkow RP; Tomlinson JS; Stewart AK; Ko CY; Talamonti MS
    J Am Coll Surg; 2007 Oct; 205(4):558-63. PubMed ID: 17903729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor.
    Nanno Y; Matsumoto I; Zen Y; Otani K; Uemura J; Toyama H; Asari S; Goto T; Ajiki T; Okano K; Suzuki Y; Takeyama Y; Fukumoto T; Ku Y
    Ann Surg Oncol; 2017 Apr; 24(4):1127-1133. PubMed ID: 27822631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
    Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
    Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.